1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMNa-ESO-01-2007, NCT00642239
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: YUNZHI-BC, NCT00647075
|
|
3.
|
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: GLU_07, NCT00772824
|
|
4.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 21
Sponsor: Other
Protocol IDs: PK01/16/08, NCT00808184
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2009-03, NCT00868569
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2009-04, NCT00874406
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Oxali04882, NCT01023633
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: BCP06, NCT01199432
|
|
9.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DERMATUX, NCT01315990
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PROFUSE-2011, NCT01468623
|
|
11.
|
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487
|
|
12.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: HDE-ALL-2011, NCT01457040
|
|
13.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2012-03, NCT01564810
|
|
14.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990
|
|
15.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 343/12, NCT01641458
|
|
16.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
|
|
17.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595050, FRE-FNCLCC- ACCORD-17-0707, EU-20848, NCT00861094
|
|
18.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: R-09-025, NCT00907543
|
|
19.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: CDK-122099, StateKeyLab, NCT01196260
|
|
20.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: GBG 52, 2008-003995-23, NCT01204437
|
|
21.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: BREC-AGC, NCT01206218
|
|
22.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CSET 1542-JANORL2, 2009-017047-34, NCT01211938
|
|
23.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FLOT4, NCT01216644
|
|
24.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 0291-1crgi09, NCT01348217
|
|
25.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: DLBS1425-0310, NCT01433562
|
Mobile | Español
